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Summary Paclitaxel (Taxol), an anti-cancer drug derived from Taxus species, was tested for its anti-migrational, anti-invasive and anti-
proliferative effect on two human glioma cell lines (GaMg and D-54Mg) grown as multicellular tumour spheroids. In addition, the direct effect
of paclitaxel on glioma cells was studied using flow cytometry and scanning confocal microscopy. Both cell lines showed a dose-dependent
growth and migratory response to paclitaxel. The GaMg cells were found to be 5-10 times more sensitive to paclitaxel than D-54Mg cells.
Paclitaxel also proved to be remarkably effective in preventing invasion in a co-culture system in which tumour spheroids were confronted
with fetal rat brain cell aggregates. Control experiments with Cremophor EL (the solvent of paclitaxel for clinical use) in this study showed no
effect on tumour cell migration, cell proliferation or cell invasion. Scanning confocal microscopy of both cell lines showed an extensive random
organization of the microtubules in the cytoplasm. After paclitaxel exposure, the GaMg and the D-54Mg cells exhibited afragmentation of the
nuclear material, indicating a possible induction of apoptosis. In line with this, flow cytometric DNA histograms showed an accumulation of
cells in the G/M phase of the cell cycle after 24 h of paclitaxel exposure. After 48 h, a deterioration of the DNA histograms was observed
indicating nuclear fragmentation.
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Cerebral tumours are responsible for approximately 2% of all
cancer deaths and malignant glioma is the most common cerebral
tumour in adults. These malignancies invade the brain extensively,
and at present the best available treatment using surgery, radiation
therapy and chemotherapy results in a median survival ofless than
18 months (Chang et al, 1983; EORTC, 1981). Most failures of
treatment occur as a result of a recurrence of the tumour.
Therefore, the need for active systematic anti-cancer agents is
urgent. It has been suggested thatpaclitaxel (Taxol) may beused in
the treatment ofgliomas either alone or in combination with other
therapeutic strategies (Tischler et al, 1992).
Paclitaxel is the first natural compound of a new class of anti-
neoplastic agents called taxanes. It was first isolated from the bark
ofthe western yew, Taxus brevifolia, and its complex structure and
anti-tumour activity in rodents were described as early as 1971
(Wani et al, 1971). The drug exerts its effects by binding tightly
to the ,3-tubulin subunit of microtubules, where it promotes
the assembly of microtubules and, thus, perturbs normal
tubulin/microtubule dynamics. During paclitaxel exposure, in
vitro polymerization of tubulin occurs even in the absence of
microtubule-associated proteins, and disaggregation of micro-
tubules is prevented during physical conditions that normally
would allow this to occur (e.g. low temperature and changes in
calcium concentration). At low concentrations (3-10 nM), pacli-
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taxel seems to block mitosis mainly by stabilizing spindle micro-
tubules, while abnormal binding of microtubule polymers is seen
at higher concentrations as a result of paclitaxel's stabilizing and
promoting characteristics (Jordan et al, 1993). This is in contrast to
agents, such as colchicine and vinblastine, that inhibit microtubule
assembly. Tissue culture studies have shown that the cell kinetic
effects of paclitaxel result in an increase in the fraction of cells in
the G2 or M phase of the cell cycle (Schiff and Horwitz, 1980).
Paclitaxel has been shown to be a potent cytotoxic agent against a
range of human malignant cell types using both cell culture and
animal xenograft models (Hruban et al, 1989; Rowinsky et al,
1990). Clinical trials have demonstrated thatpaclitaxel is an active
agent in the treatment ofmany cancers, e.g. epithelial and ovarian
cancers (McGuire et al, 1989), breast cancers (Holmes et al, 1991)
and lung cancers (Chang et al, 1993).
The in vitro sensitivity of cancer cells to chemotherapeutic
agents including paclitaxel is usually determined by growth inhibi-
tion and clonogenic assays. However, it is well known that cells
growing under different environmental conditions may respond
differently to specific therapeutic procedures. Factors such as
nutrient supply, oxygen tension, pH and other microenvironmental
conditions may affect the cellular sensitivity to paclitaxel (Carlsson
et al, 1983; Mueller-Klieser, 1987). The three-dimensional arrange-
ment of multicellular spheroids provides a cellular micromilieu
that includes different environmental conditions in different parts
of the spheroid, and it has been shown that spheroids from both
normal and malignant tissues maintain several biochemical and
morphological characteristics similar to those present in the
corresponding tissue in vivo (Sutherland et al, 1986; Sutherland,
1988). Thus, testing paclitaxel on spheroids may provide additional
information concerning paclitaxel effects in vivo.
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The present study describes the effects of paclitaxel and its
solvent (Cremophor EL) alone on glioma spheroids in vitro. Our
model is suitable for exploring the effect of the drug on growth,
directional cell migration and invasion. For this purpose, spher-
oids, from two permanent human glioma cell lines (GaMg and D-
54Mg) were confronted with normal brain cell aggregates in an
in vitro co-culture assay. In addition, the direct effect ofpaclitaxel
on glioma cells was studied using flow cytometry and scanning
confocal microscopy.
MATERIAL AND METHODS
Drug
Paclitaxel (Taxol) (Bristol-Myers Squibb Co., Princeton, NJ, USA)
was stored at4°C. Paclitaxel was prepared 1 hbefore use. The solu-
tion was diluted in complete Dulbecco's modified Eagle medium
(DMEM) (see below) to a final concentration of0.001-0.1jIg ml-'.
Cremophor EL (Sigma Chemicals, St Louis, MO, USA) was
stored at 4°C. It was prepared 1 h before use and the solution was
diluted in complete growth medium to a final concentration of
0.01-0.1jIg ml-'. To study the directeffect ofpaclitaxel onthe cell
cultures, crystalline paclitaxel was used. Crystalline paclitaxel
(lyophilized powder) was prepared 1 h before use by dissolving it
in ethanol (96%). The solution was further diluted in complete
DMEM to a final concentration of 0.001-0.1 jg ml-'. The direct
effect of paclitaxel was then studied using flow cytometry and
scanning confocal microscopy (see below for details).
Cell lines and cell culture conditions
Multicellular tumour spheroids from two human glioma cell lines
were used. The human D-54Mg cell line was kindly supplied by
Dr DD Bigner, Duke University Medical Center, Durham, NC,
USA (Bigner et al, 1981). The GaMg was obtained from a 42-
year-old woman and histologically identified as a glioblastoma
(Akslen et al, 1988).
Both cell lines were grown in Dulbecco's modified Eagle
medium supplemented with 10% heat-inactivated newbom bovine
serum, four times the prescribed concentration of non-essential
amino acids, 2% L-glutamine, penicillin (100 IU ml-') and strepto-
mycin (100 jg ml-1) (complete DMEM). The cells were cultured
at 37°C in 100% relative humidity, 95% air and 5% carbon
dioxide.
Monolayer growth
For both cell lines, 104 cells in 2 ml of complete DMEM were
seeded into 3.5-cm dishes (Nunc). The cells were then prepared
for scanning confocal microscopy and for flow cytometry
experiments.
Tumour spheroids
Tumour spheroids were initiated by the agar overlay culture method
described by Yuhas et al (1977). Briefly, spheroids were formed
by seeding 5 x 106 cells in 20 ml ofcomplete DMEM into 80-cm2
agar-coated tissue culture flasks (Nunc, Roskilde, Denmark). After
10 days in culture, spheroids with diameters between 200 and
250 jm were selected for furtherexperiments.
Tumour cell migration
Spheroids from both GaMg and D-54Mg cell lines were placed
individually into uncoated 16-mm multiwell dishes (Nunc) that
were filled with 1 ml of complete DMEM. The spheroids were
then continuously exposed to varying concentrations ofpaclitaxel
(0.001-0.1 jig ml-'). There were 12 spheroids in each treatment
group. One group was used as control (grown in complete DMEM
without drugs). The spheroids plated within 2 h, and the cellular
outgrowth from one spheroid was defined as a colony. Two
orthogonal colony diameters were measured daily by phase-
contrast microscopy over a 4-day period (96 h), and the migratory
capacities ofthe glioma cells were then determined by calculating
the colony areas from the diameter measurements. The experi-
ments were done in triplicate.
Spheroid growth
Both the GaMg cells and the D-54Mg cells were continuously
exposed to varying concentrations of paclitaxel (0.001-
0.1 jig ml-'). For each experiment, 12 spheroids were transferred
individually into 16-mm multiwell dishes (Nunc). The dishes were
base coated with 0.5 ml of0.75% DMEM agar and filled with 1 ml
of complete DMEM. One group was used as control. After treat-
ment, the dishes were incubated at 37°C. The diameters of the
spheroids were measured daily in a phase-contrast microscope
over a 15-day period and the spheroid volume was calculated. The
experiments were done in triplicate.
Brain aggregates
Fetal rat brain cells were obtained from 18-day-old fetuses of
inbred Wistar rats. The brains were dissected out under aseptic
conditions and the meningeal coverings were removed. The brains
were placed in sterile Petri dishes containing calcium- and magne-
sium-free phosphate-buffered saline (PBS; Sigma). The tissue was
cut into small pieces, washed in PBS and dissociated by serial
trypsination (0.025% trypsin; WhittakerBioproducts, Walkersville,
MD, USA) into a single cell suspension. The brain cell aggregates
were produced by seeding 6 x 106 cells in 1 ml ofgrowth medium
into 16-mm multiwell dishes (Nunc), base coated with 0.5 ml of a
non-adherent 0.75% medium agar substrate. During a4-day period,
immature brain cell aggregates wereformed. After20 days in tissue
culture, the cellular differentiation in the aggregates was complete,
resulting in a defined three-layered structure containing mature
astrocytes, oligodendrocytes and neurons with myelinated axons
and synapses present in awell-developed neuropil. Thus, the aggre-
gates show acloseresemblance to differentiated brain tissue in vivo
(Trapp et al, 1982; Bjerkvig, 1986; Bjerkvig et al, 1986).
Tumour cell invasion
Three days before confrontation with brain aggregates, the GaMg
and the D-54Mg tumour spheroids were continuously exposed to
0.01 and 0.04 jig ml-' paclitaxel respectively. This was done to
obtain an effective growth inhibition, according to the protocol
described above for spheroid growth. There were five parallels
in each of the experiments. The spheroids were then transferred
to 96-well multiwell dishes with a sterile Pasteur pipette and
confronted individually with the brain aggregates. By using a
sterile syringe and a stereomicroscope, the tumour spheroids and
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the brain aggregates were placed in close contact with each other.
The co-cultures were incubated for a 96-h period at 37°C and then
fixed for light microscopic examination and morphometric
analyses. The reduction ofbrain aggregate volume as a percentage
of the initial brain volume before confrontation was used to
quantify the invasive process (see below). The experiments were
done in duplicate.
Light microscopy
The co-cultures were fixed in 2% glutaraldehyde in 0.1 M sucrose-
adjusted sodium cacodylate buffer (300 ± 25 mOsm). After 24 h,
the specimens were washed in the same buffer without glutaralde-
hyde and post-fixed for 1 h in 1% osmium tetroxide before serial
dehydration in increasing gradients of ethanol up to 96%.
Embedding of the co-cultures in Epon 812 was performed using
graded mixtures ofeponpropylenoxide. The specimens werepoly-
merized for 48 h at 60°C. The co-cultures were then sectioned as
described below.
Morphometry
Cavalieri's principle for direct estimation ofvolume from system-
atically sampled sections was used to determine the amount of
brain tissue remaining after co-culture with tumour cell spheroids.
Serial semi-thin sections (1.5 jum) were prepared from the speci-
mens using a Reichert-Jung Microtome 2040 (Vienna, Austria).
Every 15th section was sampled, starting with one of the ten first
sections, which was randomized. The sections were then stained
with toluidine blue for light microscopic examination. The brain
tissue and the tumour tissue were easily distinguishable by the
difference in morphology. The areas of tumour tissue and
remaining brain tissue were then measured in each section by
morphometry, using an Image Analysis System (Kontron, Eching,
Germany).
The area of tumour tissue and brain tissue measured on each
slide multiplied by the distance between every sampled section
(15 x 1.5gm) gave anestimate ofthe volume between the sampled
sections. The total volume oftumourtissue and ofremaining brain
tissue was calculated by summation of all the individual volumes.
The coefficient of error in this method for estimating volume of
sections is below 5% (Gundersen and Jensen, 1987).
Control experiments
To see if Cremophor EL alone had any effect on cell growth and
migration, both GaMg and D-54Mg spheroids were treated with
0.02 and 0.1 jg ml' Cremophor EL respectively. Migration and
growth measurements were performed as described above. The
experiments were done in triplicate.
In addition, to see ifCremophor EL alone had any effect on cell
invasion, GaMg and D-54Mg spheroids were also exposed to 0.02
and 0.1jIg ml-' Cremophor EL before confronting them with the
normal rat brain cell aggregates.
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Figure 1 Tumour cell migration from GaMg and D-54Mg spheroids treated
with various concentrations of paclitaxel. Each point represents the average
of three experiments. Bars = s.e.m.
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Figure 2 Volume growth of GaMg and D-54Mg spheroids after treatment
with various concentrations of paclitaxel. A dose-dependent reduction in
spheroid growth is observed. Each point represents the average of three
experiments. Bars = s.e.m.
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(D,ur E A and F ) Photomicrographs (x 225) of co-cultures between D-5 Mg spheroids (T) and rat brain aggregates (N). (D ) Control co-culture showinganexnsv
invasion and degradation of the brain tissue. (E) Also, D-54Mg spheroids treated with 0.1 jig ml-' Cremophor EL showed invasion into the normal brain tissue.
(F) In comparison, D-54Mg spheroids treated with 0.04 jig mi-' paclitaxel showed no invasion into the brain aggregates
Scanning confocal microscopy from the migration and proliferation experiments. After 48 h, the
cells were washed in PBS and fixed for 20 min in acetone at -200C.
Exponentially growing monolayers of GaMg and D-54Mg cells They were then washed for 3 x 5 mmn in PBS before incubating
were exposed to 0.03 jig ml and 0.06-0.1 jig ml paclitaxel them with a monoclonal antibody against 0-tubulin (2 jig ml-') for
respectively. These doses were chosen based on the results obtained 1 h at 370C. The cells were then washed for 3 x 5 min in PBS
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Figure 4 Effects of paclitaxel and Cremophor EL on invasion of GaMg and
D-54Mg tumour spheroids. Volumes represent values calculated from
reconstructed image analysis of serial sections. The results are based on five
replicate cultures in two co-culture experiments. Bars = s.e.m.
before an incubation with fluorescein isothiocyanate (FITC)-conju-
gated sheep IgG against mouse immunoglobulins (20 jg ml-', both
antibodies were from Boehringer, Mannheim, Germany).
Thereafter, the monolayers were washed for 3 x 5 min in PBS and
then incubated with 0.5% RNAase in PBS for 30 s. The cells were
then washed in PBS before incubation with propidium iodine
(5 jig ml-1 in PBS). After a brief wash in PBS, the cells were
mounted using a Vectashield mounting medium (Vector
Laboratories, Burlingame, CA, USA). The cells were then
observed using a Biorad MRC-1000 scanning confocal microscope
(Biorad, Hemel Hempstead, UK).
Flow cytometry
Exponentially growing monolayers of GaMg and D-54Mg cells
were exposed to 0.03 jg ml-' and 0.1 jg ml-1 paclitaxel, respec-
tively, for 24 and 48 h. The cells were then fixed in ice-cold 96%
ethanol and stored at 4°C until use. Before DNA measurements,
the cells were incubated for 15 min with 0.5% pepsin at 37°C. The
isolated nuclei were washed in 0.9% sodium chloride and treated
for 1 min with ribonuclease (1 mg ml-' in physiological saline).
Staining of DNA was obtained by adding propidium iodine
(50 jig ml-1 in physiological saline) to the nuclei. The cellular
DNA content was measured using a FACsort flow cytometer
(Becton Dickinson, Palo Alto, CA, USA). Human peripheral blood
lymphocytes were used as a standard diploid (2c) reference. The
DNA histograms were obtained by gating a two-parameter
forward and side scatter cytogram to a one-parameter DNA
histogram. Each histogram was obtained by counting a total of
10 000 cell nuclei.
RESULTS
Tumour cell migration
The directional cell migration from the spheroids was determined
for both cell lines exposed to increasing concentrations of pacli-
taxel. Both the GaMg and the D-54Mg spheroids showed a dose-
dependent response after treatment with paclitaxel. This effect was
a rather rapid effect that progressed during the first 4 days after
plating (Figure 1).
For the GaMg cells, the outgrowth area was reduced by about
65% and 90% when continuously exposed to 0.003 and
0.01 gg ml-' paclitaxel respectively (Figure 1).
For the D-54Mg cells, a 50% reduction in outgrowth area was
obtained by adding 0.04 gg ml-1 paclitaxel. An 85% reduction was
obtained by 0.1,Ig ml-1 paclitaxel (Figure 1).
The GaMg cells were found to be more sensitive to paclitaxel
than the D-54Mg cells (Figure 1).
Spheroid growth measurements
For both cell lines, spheroids continuously exposed to paclitaxel
also showed a dose-dependent inhibition of growth. This effect
was clearly apparent after 3 days. For both cell lines, a paclitaxel
exposure of 0.01 jg ml- caused a 50% reduction in spheroid
growth (Figure 2).
At higher concentrations, there was a difference in sensitivity
between the two cell lines. For instance, 0.04 jig ml-' paclitaxel
caused a complete growth inhibition for the GaMg cells, while the
same dose forthe D-54Mg cell line caused a 75% growth reduction.
A fivefold higher paclitaxel concentration was needed to obtain
complete growth inhibition of the D-54Mg cell line (0.1 jIg ml-')
compared with the GaMg cells (0.02 jg ml-').
Tumour cell invasion
In co-cultures without paclitaxel, a replacement of brain tissue by
invading GaMg cells was observed in the sections. In the
confrontation zone, the outer layer of glial cells was lost, and the
brain aggregate volume was reduced to 54 ± 2.5% of the initial
volume (Figure 3A and Figure 4). For D-54Mg cells, the control
co-cultures presented a relative poorly defined border between
normal and tumour tissue. The brain aggregate volume was
reduced to 57 ± 2% ofthe initial volume (Figure 3E and Figure 4).
The tumour spheroids were exposed to paclitaxel 3 days before
confronting them with the brain aggregates. As shown in Figure 2,
this period was long enough to induce a growth inhibition. The co-
cultures were allowed to grow for 96 h.
After 4 days, treated GaMg spheroids showed a severe reduction
in tumour volume compared with the control experiments, and no
tumourcell invasion was observed. Itis, therefore, shown thatpacli-
taxel strongly inhibits the invasive process (Figure 3C andFigure4).
These experiments were also performed with D-54Mg spher-
oids. Again, paclitaxel prevented tumour cell invasion (Figure 3F
and Figure 4).
Control experiments
Tumourcell migration andproliferation
Cremophor EL alone had no effect on GaMg and D-54Mg tumour
spheroid growth and migration (Figure 5).
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Figure 5 Tumour cell migration and volume growth of GaMg and D-54Mg spheroids after treatment with Cremophor EL alone. No effects of Cremophor EL
were seen. Each point represents the average of three experiments. Bars=s.e.m.
Tumour cell invasion
In the co-cultures in which the GaMg and D-54Mg spheroids were
treated with Cremophor EL before confrontation, a similar reduc-
tion in brain volume was observed as shown for the control experi-
ments (Figure 3 and Figure 4). This suggests that the CremophorEL
alone did not cause any inhibitory effect on the invasion process.
Scanning confocal microscopy
Both the GaMg and D-54Mg cells showed an extensive random
organization ofthe microtubules in the cytoplasm. Most ofthe cells
had a single nucleus with a large number ofmicrotubules radiating
out from it (Figure 6A and D). After exposure to 0.03 ,ug ml-1
paclitaxel for 48 h, the GaMg cells were more contracted and the
microtubules were more strongly evident in the cytoplasm (Figure
6B and C). Ofthe GaMg cells, 30% also expressed a fragmentation
ofthe nuclear material (Figure 6B), indicating a possible induction
of apoptosis. In comparison, the D-54Mg cells were less affected
by the paclitaxel exposure and several cells expressed a similar
morphology to the control experiments. However, in these cells the
microtubules were strongly expressed also (Figure 6E). At 0.1 jIg
ml-1 paclitaxel, a nuclear fragmentation was also observed in the
D-54 Mg cell population. Some cells also showed a strong conden-
sation of the cytoplasm, which may be explained by the strong
polymerization of the microtubules commonly seen in paclitaxel-
treated cells (Figure 6F).
Flow cytometry
The flow cytometric DNA histograms showed that both the GaMg
and D-54Mg cells accumulated in the G,/M phase of the cell cycle
after 24 h ofpacitaxel exposure (0.03 and 0.1 jIg ml-' respectively).
The percentages of cells in the Gp, S and G,/M phases of the cell
cycle for the GaMg cells were 28%, 28% and 44% respectively. In
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Figure 6 (A, B and C) Scanning confocal micrographs (x 400) of GaMg
monolayer cells. (A) Control. (B) GaMg cells treated with 0.03 jg ml-'
paclitaxel showing a fragmentation of the nuclear material. (C) GaMg cells
treated with 0.03 ,ug mi-' paclitaxel also showing a more contracted
morphology. (D, E and F) Scanning confocal micrographs (x 400) of D-54Mg
monolayer cells. (D) Control. (E) D-54Mg cells treated with 0.06 ig mi-'
paclitaxel showing, at this concentration, not the same extent of nuclear
fragmentation. (F) However, at this concentration some cells showed a
strong polymerization of the microtubuli
comparison, the cell cycle distribution was 54%, 27% and 19% for
the GaMg controls (Figure 7A andB). The percentages ofcells in the
G1, S and G2/M phases of the cell cycle for the D-54Mg cells after
24 h were 30%, 34% and 36% respectively. In comparison, the cell
cycle distribution was 57%, 22% and 21% for the D-54Mg controls
(data not shown). After48 h ofpaclitaxel exposure, adeterioration of
the DNA histograms for both cell lines was evident. At 48 h, frag-
mented nuclei with an incomplete DNA content were evident to the
left oftheG, peak. This was accompanied by a decline in theG, and
G2 peaks. This probably indicates a fragmentation of the nuclear
material consistent with apoptotic cell death (Figure 7C).
DISCUSSION
In the present work, it is shown that paclitaxel strongly inhibits
glioma cell growth, migration and invasion in vitro. The assay
systems that have been used involve the use of three-dimensional
spheroids of both normal and malignant origin. Such cultures
provide a cellular microenvironment, which to some extent reflects
the in vivo situation (Bjerkvig et al, 1986). Therefore, based on the
dramatic cellular effects as seen after paclitaxel treatment, the drug
should in theory be effective for the treatment of gliomas in vivo.
Recent reports have, however, shown that when paclitaxel is admin-
istered by i.v. infusion, the cerebrospinal fluid levels reach only
0.12-8.3% of those present in concomitant plasma samples. Thus,
the drug penetrates the blood-brain barrier poorly (Glantz et al,
1995). Despite this, there is at present some evidence that paclitaxel
Figure 7 Flow cytometric DNA histograms of GaMg spheroids. (A) Control.
(B) GaMg cells after 24 h of paclitaxel treatment with 0.03 jg ml-1: an
accumulation of cells in the GJM phase of the cell cycle. (C) After 48 h of
paclitaxel exposure, a deterioration of the DNA histograms was evident
indicating a fragmentation of the nuclear material
can accumulate in brain tumourtissue, suggesting that the drug may
have a place in brain tumour therapy (Heimans et al, 1994). In line
with this, several reports have indicated that the drug can be effec-
tive against experimental brain tumours, when it is delivered either
from biodegradable polymer implants (Walter et al, 1996) or from
liposome-encapsulated vehicles (Riondel et al, 1992). Based on the
fact that there may be a clinical potential for using paclitaxel in the
treatment of gliomas, we studied the effect of the drug on three
known biological parameters (cell growth, migration and invasion)
that all play an important role in the progression of the disease
(Lund-Johansen et al, 1990).
Several critical cellular functions, such as mitosis, cell move-
ment and maintenance of cell structure, are performed by
cytoskeletal elements in which the microtubular system plays a
major role. Paclitaxel represents a mitotic inhibitor in which the
mechanism of action is to enhance the rate and yield of micro-
tubular assembly preventing microtubular depolymerization
(Schiff et al, 1979). Several reports have shown that such effects
induce a block of cells in the G2/M phase of the cell cycle
(Gangemi et al, 1995; Chang et al, 1996; Wahl et al, 1996) and our
results support these findings (Figure 7). The reduced growth as
seen in the spheroids can therefore be explained by an inhibition of
cell division, which has also been shown by other authors (Teng et
al, 1977; Crossin and Camey, 1981; Otto and De Assua, 1983). In
addition, the scanning confocal microscopy indicated that both the
GaMg and the D-54Mg cells underwent a nuclearfragmentation as
a result of paclitaxel exposure (Figure 6B). Such a fragmentation
may imply that paclitaxel also induces apoptosis in the glioma
cells. That the nuclear material is deteriorating is further supported
by the flow cytometric observations showing a fragmentation of
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the nuclear DNA content with a reduction in G1 and G2/M cells
after 48 h of paclitaxel exposure (Figure 7). Similar observations
have also been made in fibroblasts by Wahl et al, 1996). The
outgrowth assay measures the ability of the cells organized in a
three-dimensional structure to migrate and to proliferate. Cell
migration is the dominating process that occurs during the first
days after plating (Storme et al, 1981). Notably, paclitaxel caused
an inhibition of cell migration for both cell lines (Figure 1). This
effect was dose dependent, resulting in a complete migratory arrest
of the GaMg cells after 0.02 ,ug ml-' paclitaxel exposure. The D-
54Mg cells were also inhibited but were at least 5-10 times less
sensitive to paclitaxel than the GaMg cells. The biological mecha-
nisms explaining this difference are at present not completely
understood. Other groups have also observed differences in sensi-
tivity to paclitaxel between cell lines, and it has been suggested
that this may be partly caused by a variability in the expression of
the multidrug resistance gene (MDR]) (Helson et al, 1993;
Berkova and Page, 1995). In theory, the results may suggest that
the D-54Mg cell's resistance to paclitaxel is not related to its
inability to target microtubules, but to the inability ofthe D-54Mg
cells to undergo apoptosis (Gangemi et al, 1995). However, as
indicated by the flow cytometric experiments, a deterioration of
the DNA histograms was observed for the D-54Mg cells exposed
to paclitaxel, which indeed indicates that the D-54Mg cells are
able to undergo apoptosis. In line with our results, other groups
have also shown that human glioma cell lines are sensitive to
paclitaxel (Cahan et al, 1994).
The scanning confocal microscopy revealed a large variation in
the cellular morphology after paclitaxel exposure within the cell
lines. This was most evident for the GaMg cells and suggests that
paclitaxel may induce multiple biological effects within a hetero-
geneous tumour cell population (Figure 6A-C). The influence of
tumour heterogeneity on the efficacy of paclitaxel is caused not
only by cell clones exhibiting inherent differential sensitivities, but
also by the presence of subpopulations of cells differing in meta-
bolic and physiological states. Within spheroids, steep gradients
can exist for cellular oxygen levels, nutrients, pH and glucose
concentrations (Mueller-Klieser, 1987). All these factors may
affect glioma cell growth, migration and invasion and will probably
interfere with the direct biological effects induced by paclitaxel.
Paclitaxel reduces cellular motility through interference with
the microtubules, a fundamental part ofthe cytoskeleton. Thus, the
present study confirms other studies (Stracke et al, 1993;
Verschueren et al, 1994; Sollott et al, 1995), but contradicts the
findings of Silbergeld et al (1995) who found that paclitaxel
increased the motility ofglioma cells.
In line with the inhibition of migration, we also showed that
paclitaxel reduced the invasive capacity of the tumour cells
(Figure 3), implying that the drug is active in inhibiting tumour
cell invasion in vivo. Notably, the paclitaxel-treated glioma cells
were not able to infiltrate the brain cell aggregates. This implies
that the treated tumour cells were not able to move in the co-
culture system. It is well known that complex interactions take
place between normal tissue and tumour cells. This occurs in a
microenvironment in which growth factors and other cellular
components are exchanged between the two cell populations in a
paracrine fashion. Such factors were not able to induce the inva-
sive process. Thus, our data support the findings of other groups
showing an inhibition ofMDCK and prostate tumour cell invasion
into Boyden chambers and Matrigel (Stearns and Wang, 1992;
Dugina et al, 1995). Interestingly, Cremophor EL (the solvent for
paclitaxel for clinical use) had no effect on cell growth, migration
and invasion in our assay systems at the concentrations used. This
indicates that the cellular effects as shown in our three-dimen-
sional assays were not caused by any interference with the pacli-
taxel solvent. These observations may contradict other findings
showing cytotoxic effects of Cremophor EL on tumour cells
(Liebmann et al, 1993; Nygren et al, 1995). However, the results
that were obtained in these studies were based on experiments
performed on monolayer cell cultures. It is well known that such
cultures, in general, are more sensitive to therapy compared with
multicellular spheroids that have been used in the present study
(Bjerkvig, 1992). At present, it is therefore not clear to what extent
Cremophor EL affects a malignant three-dimensional tissue struc-
ture. In conclusion, we have shown that paclitaxel inhibits the
invasive growth of human glioma cell in vitro, using a three-
dimensional co-culture system involving both tumour and normal
brain cells. The effects observed by paclitaxel imply that the drug
is strongly active towards this tumour type. Thus, future studies
should probably focus on new administration routes of paclitaxel
to gliomas.
ACKNOWLEDGEMENTS
This work was supported by grants from the Department of
Neurosurgery, Liubeck, the Norwegian Cancer Society, the
Norwegian Research Council and Bristol-Myers Squibb Oncology,
H0vik, Frank Mohn A/S and Familien Brynildsens Legat.
Technical assistance from Ms E Pawlak is greatly appreciated.
REFERENCES
Akslen LA, Andersen KJ and Bjerkvig R (1988) Characteristics ofhuman and rat
glioma cells grown in a defined medium. Anticancer Res 8: 797-804
Berkova N and Page M (1995) Addition of hTNF alpha potentiates cytotoxicity of
taxol in human ovarian cancer lines. Anticancer Res 15 (3): 863-866
Bigner DD, Bigner SH, Ponten J, Westermark B, Mahaley MS, Ruoslahti E,
Herschman H, Eng LF and Wikstrand CJ (1981) Heterogeneity ofgenotypic
and phenotypic characteristics of fifteen permanent cell lines derived from
human gliomas. JNeuropathol Exp Neurol 15: 201-227
Bjerkvig R (1986) Reaggregation of fetal rat brain cells in a stationary culture
system. II: ultrastructure characterisation. In Vitro Cell Dev Biol 22: 193-200
Bjerkvig R (ed.) (1992) Spheroid Cultures in CancerResearch. CRP Press Inc.:
Florida
Bjerkvig R, Laerum OD and Mella 0 (1986) Glioma cell interaction with fetal rat
brain aggregates in vitro and with brain tissue in vivo. Cancer Res 46:
4071-4079
Bjerkvig R, Steinvaag SK and Laerum OD (1986) Reaggregation offetal rat brain
cells in a stationary culture system. I: methodology and cell identification. In
Vitro Cell Dev Biol 22: 180-192
Cahan MA, Walter KA, Colvin OM and Brem H (1994) Cytotoxicity of taxol in
vitro against human and rat malignant brain tumors. Cancer Chemother
Pharmnacol 33: 441-444
Carlsson J, Nilsson K, Westermark B, Ponten J, Sundstrom C, Carsson E, Bergh J,
Pahlman S, Busch C and Collins VP (1983) Formation and growth of
multicellular spheroids ofhuman origin. IntJ Cancer 31: 523-533
Chang AY, Kim K and Glick J (1993) Phase II study oftaxol, merbarone, and
piroxantrone in stage IV non-small-cell lung cancer: the Eastem Cooperative
Oncology Group results. J Natl Cancer Inst 85: 388-394
Chang CH, Horton J, Schoenfeld D, Salazer 0, Perez-Tamayo R, Kramer S,
Weinstein A, Nelson JS and Tsakuda Y (1983) Comparison ofpostoperative
radiotherapy and combined postoperative radiotherapy and chemotherapy in
the multidisciplinary management ofmalignant gliomas. Cancer 52: 997-1007
Chang YF, Li LL, Wu CW, Liu TY, Lul WY, Peng FK and Chi CW (1996) Paclitaxel
induced apoptosis in human gastric carcinoma cell lines. Cancer 77: 14-18
Crossin KL and Camey DH (1981) Microtubule stabilization by Taxol inhibits
initiation of DNA synthesis by thrombin and by epidermal growth factor. Cell
27: 341-350
@ Cancer Research Campaign 1997 British JournalofCancer (1997) 75(12), 1744-17521752 A-JA Terzis etal
Dugina VB, Alexandrova AY, Lane K, Bulanova E and Vasiliev JM (1995) The role
ofthe microtubular system in the cell response to HGF/SF. J Cell Sci 108:
1659-1667
Eortc Brain Tumour Group (1981) Evaluation ofCCNU, VM-26 plus CCNU, and
procarbazine in supratentorial brain gliomas. JNeurosurg 55: 27-31
Gangemi RMR, Tiso M, Marchetti C, Severi AB and Fabbi M (1995) Taxol
cytoxicity on human leukemia cell lines is a function oftheir susceptibility to
programmed cell death. Cancer Chemother Pharmacol 36: 385-392
Glantz MJ, Choy H, Kearns CM, Mills PC, Wahlberg LU, Zuhowski EG, Calabresi
P and Egorin MJ (1995) Paclitaxel disposition in plasma and central nervous
systems ofhumans and rats with brain tumours. JNatl Cancer Inst 87 (14):
1077-1081
Gundersen HJG and Jensen EB (1987) The efficiency ofsystematic sampling in
stereology and its prediction. JMicroscopy 147: 229-263
Heimans JJ, Vermorken JB, Wolbers FG, Eeltink JG, Meijer OW, Taphoom MJ and
Beijnen JH (1994) Paclitaxel (Taxol) concentrations in brain tumour tissue. Ann
Oncol 5 (10): 951-953
Helson L, Helson C, Malik S, Ainsworth S and Mangiardi J (1993) A saturation
threshold for taxol cytotoxicity in human glial and neuroblastoma cells.
Anticancer Drugs 4: 487-490
Holmes FA, Frye D, Theriault RL, Walters RS, Forman AD, Newton LK, Buzdar
AU and Hortobagy GN (1991) Phase II study ofTaxol in patients with
metastatic breast cancer. Proc Am Soc Clin Oncol 10: 60-63
Hruban RH, Yardley JH, Donehower RC and Boitnott JK (1989) Taxol toxicity.
Epithelial necrosis in the gastrointestinal tract associated with polymerized
microtubule accumulation and mitotic arrest. Cancer 63: 1944-1950
Jordan MA, Toso RJ, Thrower D and Wilson L (1993) Mechanisms ofmitotic block
and inhibition ofcell proliferation by Taxol at low concentrations. Proc Natl
Acad Sci USA 90: 9552-9556
Liebmann JE, Cook JA, Lipschultz C, Teague D, Fischer J and Mitchell JB (1993)
Cytotoxic studies ofpaclitaxel (Taxol) in human tumour cell lines. BrJ Cancer
68: 1104-1109
Lund-Johansen M, Engebraaten 0, Bjerkvig R and Laerum OD (1990) Invasive
glioma cells in tissue culture. Anticancer Res 10: 1135-1152
McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine RC, Ettinger DS,
Armstrong DK and Donehower RC (1989) Taxol: a unique antineoplastic agent
with significant activity in advanced ovarian epithelial neoplasms. Ann Intern
Med 111: 273-279
Mueller-Klieser W (1987) Multicellular spheroids. A review on cellular aggregates
in cancer research. J CancerRes Clin Oncol 113: 101-122
Nygren P, Csoka K, Jonsson B, Fridborg H, Bergh J, Hagberg H, Glimelius B,
Brodin 0, Tholander B and Kreuger A (1995) The cytotoxic activity ofTaxol
in primary cultures oftumour cells from patients is partly mediated by
Cremophor EL. BrJ Cancer 71: 478-481
Otto AM and DE Assua LJ (1983) Microtubule-disrupting agents can independently
affect the prereplicable period and the entry into S phase stimulated by
prostaglandin F2 and fibroblastic growth factor. J Cell Physiol 115: 15-22
Riondel J, Jacrot M, Fessi H, Puisieux F and Potier F (1992) Effects offree and
liposome-encapsulated taxol on two brain tumours xenografted into nude mice.
In Vivo 6: 23-27
Rowinsky EK, Cazenave LA and Donehower RC (1990) Taxol: a novel
investigational antimicrotubule agent. JNatl Cancer Inst 82: 1247-1259
SchiffPB and Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast
cells. Proc NatlAcadSci USA 77: 1561-1565
Schiff PB, Fant J and Horwitz SB (1979) Promotion ofmicrotubule assembly in
vitro by Taxol. Nature 277: 665-667
Silbergeld DL, Chicoine MR and Madsen CL (1995) In vitro assessment oftaxol for
human glioblastoma: chemosensitivity and cellular locomotion. Anticancer
Drugs 6: 270-276
Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, Kuzuya M, Froehlich
JP, Crow MT, Lakatta EG and Rowinsky EK (1995) Taxol inhibits neointimal
smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 95:
1869-1876
Steams ME and Wang M (1992) Taxol blocks processes essential for prostate
tumour cell (PC-3 ML) invasion and matastases. Cancer Res 52: 3776-3881
Storme G, Mareel MM and De Bruyne G (1981) Influence ofcell number on
directional migration ofMO4 cells in vitro. Arch Gesschwulstforsch 51: 45-50
Stracke ML, Soroush M, Liotta LA and Schiffmann E (1993) Cytoskeletal agents
inhibit motility and adherence ofhuman tumour cells. Kidney Int 43: 151-157
Sutherland RM (1988) Cell and environment interactions in tumour microregions:
the multicellular spheroid model. Science 240: 177-184
Sutherland RM, Freyer J and Mueller-Klieser W (1986) Cellular growth and
metabolic adaptations to nutrient stress environments in tumour microregions.
IntJRadiat Oncol Biol Phys 12: 611-615
Teng MH, Bartholomew JC and Bissel MJ (1977) Synergism between anti-
microtubule agents and growth stimulants in enhancement ofcell cycle
traverse. Nature 268: 739-741
Tischler RB, SchiffPB, Geard CR and Hall EJ (1992) Taxol: a novel radiation
sensitizer. IntJRadiat Oncol Biol Phys 22: 613-617
Trapp BD, Webster HD, Johnson D, Quarles RH, Cohen SR and Murray MR (1982)
Myelin formation in rotation-mediated aggregating cell cultures:
immunocytochemical, electron microscopic and biochemical observations.
JNeurosci 2: 986-993
Verschueren H, Dewit J, De-Braekeleer J, Schirrmacher V and De-Baetselier P
(1994) Motility and invasive potency ofmurine T-lymphoma cells: effect of
microtubule inhibitors. Cell BiolInt 18: 11-19
Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demers GW and
Galloway DA (1996) Loss ofnormal p53 function confers sensitization to
Taxol by increasing G2/M arrest and apoptosis. Nature Med2: 72-79
Walter KA, Cahan MA, Gur A, Tyler B, Hilton J, Colvin OM, Burger PC,
Domp A and Brem H (1994) Interstitial taxol delivered from abiodegradable
polymer implant against experimental malignant glioma. Cancer Res 54:
2207-2212
Wani MC, Taylor HL, Wall ME, Coggon P and McPhail AT (1971) Plant
antitumour agents. VI. The isolation and structure ofTaxol, a novel
antileukemic and antitumor agent from Taxus brevifolia. JAm Chem Soc 93:
2325-2327
Yuhas JM, Li AP, Martinez AO and Ladman AJ (1977) A simplified method
for production and growth ofmulticellular spheroids. Cancer Res 37:
3639-3643
British Journal ofCancer(1997) 75(12), 1744-1752 C)CancerResearch Campaign 1997